GHRH Receptor Activation & Visceral Fat Reduction
Tesamorelin — Trans-3-Hexenoic Acid Modified GHRH Analog
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence of GHRH with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification significantly enhances metabolic stability compared to native GHRH while preserving full biological activity at the GHRH receptor.
Tesamorelin is notable for being the only GHRH analog to receive FDA approval: it is approved under the brand name Egrifta® for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. This clinical validation provides a robust human pharmacokinetic, pharmacodynamic, and safety dataset that distinguishes tesamorelin from most research peptides.
Tesamorelin consists of the complete 44-amino-acid sequence of human GHRH (hGHRH[1-44]-NH2) with a trans-3-hexenoic acid moiety conjugated to the alpha-amino group of the N-terminal tyrosine residue. This N-terminal modification is the key structural feature that confers enhanced stability against dipeptidyl peptidase IV (DPP-IV) cleavage — the primary mechanism of native GHRH degradation.
The molecular weight is 5,135.9 Daltons. Unlike CJC-1295, which achieves stability through amino acid substitutions, tesamorelin achieves stability through the N-terminal fatty acid conjugation while retaining the complete native GHRH sequence.
Tesamorelin acts as a selective agonist at the GHRH receptor (GHRHR) on pituitary somatotroph cells, activating the same adenylyl cyclase → cAMP → PKA signaling cascade as native GHRH. This triggers the synthesis and pulsatile release of endogenous growth hormone, which in turn stimulates hepatic IGF-1 production.
The mechanism underlying tesamorelin's specific effect on visceral adipose tissue (VAT) involves GH-mediated stimulation of lipolysis in visceral fat depots. GH activates hormone-sensitive lipase (HSL) in adipocytes, promoting the breakdown of stored triglycerides. Visceral adipocytes are particularly sensitive to GH-mediated lipolysis due to their higher density of GH receptors and lower sensitivity to insulin's anti-lipolytic effects compared to subcutaneous adipocytes.
Tesamorelin is a synthetic version of GHRH (growth hormone-releasing hormone) that has actually been FDA-approved since 2010. It's sold under the brand name Egrifta® for reducing excess abdominal fat in HIV patients on antiretroviral therapy. This makes it one of the few peptides in this guide with genuine FDA approval and published Phase III clinical trial data.
Like CJC-1295, Tesamorelin stimulates the pituitary gland to release growth hormone by mimicking the natural GHRH signal. The key difference is its specific clinical validation for visceral fat reduction. In FDA-approved trials, Tesamorelin produced statistically significant reductions in trunk fat in HIV patients, with effects maintained over 52 weeks of treatment. It works through the GH/IGF-1 axis, which regulates fat metabolism alongside muscle and bone effects.
Visceral fat (the fat stored around internal organs) is metabolically distinct from subcutaneous fat and is strongly associated with cardiovascular and metabolic disease risk. Tesamorelin's FDA approval for visceral fat reduction gives it a level of clinical credibility that most research peptides lack. Researchers studying metabolic syndrome, lipodystrophy, or GH axis biology have a robust clinical dataset to reference.
Tesamorelin is unique in this catalog because it has FDA approval for a specific indication, meaning it has completed the full clinical trial process. The research-grade lyophilized powder supplied by Purgo Labs is for laboratory use only and differs from the clinical formulation. Its approval status makes it one of the most clinically validated GHRH analogs available for research.
Activates GHRH receptor on pituitary somatotrophs, triggering adenylyl cyclase → cAMP → PKA cascade and pulsatile GH release.
GH activates hormone-sensitive lipase in visceral adipocytes, promoting triglyceride breakdown and VAT reduction.
Secreted GH drives hepatic IGF-1 production, mediating downstream anabolic and metabolic effects.
N-terminal trans-3-hexenoic acid modification prevents DPP-IV cleavage, extending biological half-life vs. native GHRH.
1 cited study — model, sample size, outcome, and effect size from published literature.
| Study | Model | Sample | Outcome | Effect Size | Level |
|---|---|---|---|---|---|
Falutz J, et al. (2010) Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HI… PubMed | Human — Phase III RCT | n=412 | Significant reduction in visceral adipose tissue (VAT) in HIV-lipodystrophy | VAT reduction: ~15% vs. placebo; statistically significant (p<0.001) | Phase III |
Growth Research
≥99% purity · Third-party tested
Use code Health for 15% off
Fast FedEx shipping · 60-day guarantee
| Peptide Class | GHRH analog (44 amino acids + N-terminal modification) |
| Molecular Weight | 5,135.9 Da |
| FDA Approval | Egrifta® — HIV-associated lipodystrophy (VAT reduction) |
| Receptor Target | GHRH receptor (GHRHR) on pituitary somatotrophs |
| Key Modification | trans-3-hexenoic acid N-terminal conjugation (DPP-IV resistance) |
| Available Sizes | 10mg vials |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Purgo Labs offers Tesamorelin with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.
Purchase Tesamorelin at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.
